Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ANV419 First in Human Study Phase 1: Open-label, Dose Escalation Study of ANV419 As Single Agent and in Combination with Ipilimumab in Patients with Relapsed/Refractory Advanced Solid Tumors

NCT04855929 is registered in ClinicalTrials.gov with Anaveon AG as lead sponsor.

NCT NCT04855929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04855929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ANV419 First in Human Study Phase 1: Open-label, Dose Escalation Study of ANV419 As Single Agent and in Combination with Ipilimumab in Patients with Relapsed/Refractory Advanced Solid Tumors
Lead sponsor
Anaveon AG
Phase
Phase 1
Overall status
Completed
Start date
May 25, 2021
Completion date
July 18, 2024
Enrollment
55 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adult disease, advanced solid tumor, lung cancer